Immutep Limited (ASX:IMM)
0.0750
+0.0030 (4.17%)
Apr 16, 2026, 4:11 PM AEST
Immutep Revenue
Immutep had revenue of 4.10M AUD in the half year ending December 31, 2025, with 4,506.79% growth. This brings the company's revenue in the last twelve months to 4.13M, up 7,650.57% year-over-year. In the fiscal year ending June 30, 2025, Immutep had annual revenue of 59.71K, down -49.86%.
Revenue (ttm)
4.13M
Revenue Growth
+7,650.57%
P/S Ratio
13.39
Revenue / Employee
255.57K
Employees
31
Market Cap
106.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 59.71K | -59.38K | -49.86% |
| Jun 30, 2024 | 119.09K | -72.63K | -37.88% |
| Jun 30, 2023 | 191.72K | -62.67K | -24.63% |
| Jun 30, 2022 | 254.39K | -58.45K | -18.68% |
| Jun 30, 2021 | 312.84K | -7.45M | -95.97% |
| Jun 30, 2020 | 7.77M | 6.47M | 499.78% |
| Jun 30, 2019 | 1.29M | -2.34M | -64.42% |
| Jun 30, 2018 | 3.64M | 2.84M | 354.63% |
| Jun 30, 2017 | 800.46K | 625.41K | 357.27% |
| Jun 30, 2016 | 175.05K | - | - |
| Jun 30, 2015 | - | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | - | - | - |
| Jun 30, 2006 | - | - | - |
| Jun 30, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Botanix Pharmaceuticals | 21.92M |
| Radiopharm Theranostics | 16.28M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Prescient Therapeutics | 4.27M |
| Imugene | 3.94M |
| Proteomics International Laboratories | 3.21M |
Immutep News
- 12 hours ago - IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 18 hours ago - Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles - Benzinga
- 22 hours ago - IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial Viability : Levi & Korsinsky - PRNewsWire
- 23 hours ago - Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - GlobeNewsWire
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP - GlobeNewsWire
- 1 day ago - Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP - PRNewsWire
- 5 days ago - IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 6 days ago - Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP - PRNewsWire